We are live on ! Find out more
BTAI icon

BioXcel Therapeutics
BTAI

108 hedge funds and large institutions have $378M invested in BioXcel Therapeutics in 2021 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 37 increasing their positions, 32 reducing their positions, and 32 closing their positions.

New
Increased
Maintained
Reduced
Closed

16% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 32

0.13% more ownership

Funds ownership: 2.8% → 2.93% (+0.13%)

7% less funds holding

Funds holding: 116 → 108 (-8)

20% less capital invested

Capital invested by funds: $475M → $378M (-$96.5M)

25% less first-time investments, than exits

New positions opened: 24 | Existing positions closed: 32

38% less call options, than puts

Call options by funds: $4.94M | Put options by funds: $7.94M

Holders
108
Holders Change
-8
Holders Change %
-6.9%
% of All Funds
1.88%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
24
Increased
37
Reduced
32
Closed
32
Calls
$4.94M
Puts
$7.94M
Net Calls
-$3M
Net Calls Change
-$3.83M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$30.2M
2
AS
Altshuler Shaham
Israel
+$9.34M
3
CCM
CAAS Capital Management
New York
+$7.91M
4
GCM
Ghisallo Capital Management
Massachusetts
+$7.67M
5
State Street
State Street
Massachusetts
+$6.24M

Top Sellers

Rank Fund Capital Flow
1
LGM
Logos Global Management
California
-$17.3M
2
FLAM
First Light Asset Management
Minnesota
-$15.5M
3
LCG
Lisanti Capital Growth
New York
-$4.01M
4
CM
Caption Management
Oklahoma
-$1.73M
5
ACA
Apis Capital Advisors
New York
-$1.55M
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Advisers
26
Two Sigma Advisers
New York
$1.9M -$507K -931 -19%
MIM
27
Monashee Investment Management
Massachusetts
$1.74M +$2.04M +3,750 New
N
28
Nuveen
North Carolina
$1.62M +$79K +145 +4%
HF
29
HRT Financial
New York
$1.54M +$1.51M +2,774 +507%
Bank of New York Mellon
30
Bank of New York Mellon
New York
$1.44M -$368K -676 -18%
Swiss National Bank
31
Swiss National Bank
Switzerland
$1.23M +$306K +562 +27%
ACM
32
ACT Capital Management
Pennsylvania
$1.22M +$1.43M +2,625 New
KCM
33
Kennedy Capital Management
Missouri
$1.18M -$28.9K -53 -2%
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
34
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
$1.16M +$1.36M +2,500 New
Hudson Bay Capital Management
35
Hudson Bay Capital Management
Connecticut
$1.16M +$1.36M +2,500 New
AA
36
ALPS Advisors
Colorado
$943K -$397K -728 -26%
Squarepoint
37
Squarepoint
New York
$911K +$1.07M +1,959 New
WMSA
38
Weiss Multi-Strategy Advisers
New York
$825K +$214K +392 +28%
AA
39
AlphaCentric Advisors
Puerto Rico
$727K – – –
Deutsche Bank
40
Deutsche Bank
Germany
$704K +$13.1K +24 +2%
HWAM
41
Hennion & Walsh Asset Management
New Jersey
$618K +$724K +1,329 New
CL
42
CSS LLC
Illinois
$616K -$524K -962 -42%
California State Teachers Retirement System (CalSTRS)
43
California State Teachers Retirement System (CalSTRS)
California
$612K +$61.6K +113 +9%
UBS AM
44
UBS AM
Illinois
$599K +$136K +250 +24%
KCM
45
Knoll Capital Management
Florida
$581K – – –
TAM
46
Tocqueville Asset Management
New York
$572K +$176K +322 +35%
BNP Paribas Financial Markets
47
BNP Paribas Financial Markets
France
$519K +$303K +556 +99%
CIAS
48
Capital Investment Advisory Services
North Carolina
$477K -$6K -11 -1%
HHAM
49
HITE Hedge Asset Management
Massachusetts
$476K +$559K +1,025 New
Jane Street
50
Jane Street
New York
$468K -$421K -772 -43%
1
2
3 4 5

BTAI Hedge Fund Activity: Q2 2021 in Review

108 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q2 2021, worth a combined $378M — down 20% from $475M a quarter earlier.

Sellers outnumbered buyers: 32 funds closed out of BTAI and 24 opened new positions — a net loss of 8 holders — while 32 trimmed existing stakes and 37 added.

The largest buyer was Fidelity Investments, adding an estimated $30.2M. The largest seller was Logos Global Management, exiting entirely with an estimated $17.3M sold.

  • 108 institutional investors held BioXcel Therapeutics (BTAI) as of Q2 2021, down from 116 in Q1 2021.
  • Funds reported $378M of BioXcel Therapeutics stock for Q2 2021, down 20% quarter-over-quarter.
  • 24 funds opened new BioXcel Therapeutics positions in Q2 2021 and 32 closed out, a net change of -8 holders.
  • The largest BioXcel Therapeutics buyer in Q2 2021 was Fidelity Investments, an estimated $30.2M added.
  • The largest BioXcel Therapeutics seller in Q2 2021 was Logos Global Management, an estimated $17.3M sold.

Based on aggregated 13F filings for Q2 2021.